This week a special documentary premiered in New York City to a special VIP crowd of medical experts, sports professionals and trendsetters.
Blue Horizon International hosted the private screening of Stem Cells: The Next Frontier on Tuesday, Feb. 13. The evening included sessions with the organizations that provided a wealth of information on the future of this groundbreaking miracle of life-saving stem cells therapies to the world.
Guests at the event included H.E. Peter Kmec, Ambassador Extraordinary and Plenipotentiary of the Slovak Republic to the United States, retired NFL player Kirk Barton, and patient Yesenia Torres.
BHI Therapeutic Sciences carries a prolific philosophy that stem cells are the future of medicine. The organization is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby). Stem cells are a special kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.
The film focused on the hope for change in the medical field that will potentially change the lives of millions of patients across the planet. The documentary is thoughtful and brings forth a message that not enough is being done. Without the brave methods of BHI the chances of positive change are imminent.
BHITS has a treatment and research facility in Slovakia, as well as clinic facilities in China and Jamaica. More then 3000 stem cell treatments have been successfully performed in our clinics.
BHITS has conducted several clinical studies testing the safety and efficacy of human umbilical cord blood (hUCB) stem cells. Our clinical studies have provide support for the short and long-term safety of hUCB stem cells for therapy of different medical conditions, including chronic inflammation, musculoskeletal conditions, stroke and spinal cord injury.
The intent is to develop hUCB product based therapies in Investigational New Drug Phase 1 clinical trials in order to extend lifespans and improve the quality of life for patients. Please visit www.bhisciences.com and BHI Therapeutic Sciences for more information on investment opportunities.
To catch a glimpse of their awe-inspiring work in the trailer of their documentary check out the link here.
Photos by Benno Klandt